HIV type 2 Envelope protein (aa 390 - 702), recombinant protein from E. coli
Recombinant Human Immunodeficiency Virus Type 2 (HIV-2) envelope antigen (amino acids 390-702). 34kDa with Beta-galactosidase (114kDa) fused at the N-terminus, was expressed in E. coli.
> 95% pure (SDS-PAGE (Bradford method))
1 mg/ml (OD280nm)
0.01M Na2CO3; 0.01M Na3EDTA, 0.014M beta- mercaptoethanol; 0.05% Tween 20.
2-8°C short term, -20°C long term
HIV-1 and HIV-2 appear to package their RNA differently. HIV-1 binds to any appropriate RNA whereas HIV-2 preferentially binds to mRNA which creates the Gag protein itself. This means that HIV-1 is better able to mutate. HIV-2 is transmitted in the same ways as HIV-1: Through exposure to bodily fluids such as blood, semen, tears and vaginal fluids.Immunodeficiency develops more slowly with HIV-2.HIV-2 is less infectious in the early stages of the virus than with HIV-1.The infectiousness of HIV-2 increases as the virus progresses.Major differences include reduced pathogenicity of HIV-2 relative to HIV-1, enhanced immune control of HIV-2 infection and often some degree of CD4-independence. Despite considerable sequence and phenotypic differences between HIV-1 and 2 envelopes, structurally they are quite similar. Both membrane-anchored proteins eventually form the 6-helix bundles from the N-terminal and C-terminal regions of the ectodomain, which is common to many viral and cellular fusion proteins and which seems to drive fusion.HIV-1 gp41 helical regions can form more stable 6-helix bundles than HIV-2 gp41 helical regions however HIV-2 fusion occurs at a lower threshold temperature (25°C), does not require Ca2+ in the medium, is insensitive to treatment of target cells with cytochalasin B, and is not affected by target membrane glycosphingolipid composition.
HIV-2 Envelope 201 Antigen; Retroviridae; Lentivirus; Human immunodeficiency virus 2